Immune oncology, immune responsiveness and the theory of everything

Tolga Turan, Deepti Kannan, Maulik Patel, J. Matthew Barnes, Sonia G. Tanlimco, Rongze Lu, Kyle Halliwill, Sarah Kongpachith, Douglas E. Kline, Wouter R. Hendrickx, Alessandra Cesano, Lisa H. Butterfield, Howard L. Kaufman, Thomas J. Hudson, Davide Bedognetti, Francesco Marincola, Josue Samayoa

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Anti-cancer immunotherapy is encountering its own checkpoint. Responses are dramatic and long lasting but occur in a subset of tumors and are largely dependent upon the pre-existing immune contexture of individual cancers. Available data suggest that three landscapes best define the cancer microenvironment: immune-active, immune-deserted and immune-excluded. This trichotomy is observable across most solid tumors (although the frequency of each landscape varies depending on tumor tissue of origin) and is associated with cancer prognosis and response to checkpoint inhibitor therapy (CIT). Various gene signatures (e.g. Immunological Constant of Rejection - ICR and Tumor Inflammation Signature - TIS) that delineate these landscapes have been described by different groups. In an effort to explain the mechanisms of cancer immune responsiveness or resistance to CIT, several models have been proposed that are loosely associated with the three landscapes. Here, we propose a strategy to integrate compelling data from various paradigms into a "Theory of Everything". Founded upon this unified theory, we also propose the creation of a task force led by the Society for Immunotherapy of Cancer (SITC) aimed at systematically addressing salient questions relevant to cancer immune responsiveness and immune evasion. This multidisciplinary effort will encompass aspects of genetics, tumor cell biology, and immunology that are pertinent to the understanding of this multifaceted problem.

Original languageEnglish
Article number50
JournalJournal for ImmunoTherapy of Cancer
Volume6
Issue number1
DOIs
Publication statusPublished - 5 Jun 2018

Fingerprint

Neoplasms
Immunotherapy
Immune Evasion
Tumor Microenvironment
Advisory Committees
Allergy and Immunology
Cell Biology
Inflammation
Therapeutics
Genes

Keywords

  • Cancer immunotherapy
  • Checkpoint inhibitors
  • Immune resistance

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Turan, T., Kannan, D., Patel, M., Matthew Barnes, J., Tanlimco, S. G., Lu, R., ... Samayoa, J. (2018). Immune oncology, immune responsiveness and the theory of everything. Journal for ImmunoTherapy of Cancer, 6(1), [50]. https://doi.org/10.1186/s40425-018-0355-5

Immune oncology, immune responsiveness and the theory of everything. / Turan, Tolga; Kannan, Deepti; Patel, Maulik; Matthew Barnes, J.; Tanlimco, Sonia G.; Lu, Rongze; Halliwill, Kyle; Kongpachith, Sarah; Kline, Douglas E.; Hendrickx, Wouter R.; Cesano, Alessandra; Butterfield, Lisa H.; Kaufman, Howard L.; Hudson, Thomas J.; Bedognetti, Davide; Marincola, Francesco; Samayoa, Josue.

In: Journal for ImmunoTherapy of Cancer, Vol. 6, No. 1, 50, 05.06.2018.

Research output: Contribution to journalArticle

Turan, T, Kannan, D, Patel, M, Matthew Barnes, J, Tanlimco, SG, Lu, R, Halliwill, K, Kongpachith, S, Kline, DE, Hendrickx, WR, Cesano, A, Butterfield, LH, Kaufman, HL, Hudson, TJ, Bedognetti, D, Marincola, F & Samayoa, J 2018, 'Immune oncology, immune responsiveness and the theory of everything', Journal for ImmunoTherapy of Cancer, vol. 6, no. 1, 50. https://doi.org/10.1186/s40425-018-0355-5
Turan T, Kannan D, Patel M, Matthew Barnes J, Tanlimco SG, Lu R et al. Immune oncology, immune responsiveness and the theory of everything. Journal for ImmunoTherapy of Cancer. 2018 Jun 5;6(1). 50. https://doi.org/10.1186/s40425-018-0355-5
Turan, Tolga ; Kannan, Deepti ; Patel, Maulik ; Matthew Barnes, J. ; Tanlimco, Sonia G. ; Lu, Rongze ; Halliwill, Kyle ; Kongpachith, Sarah ; Kline, Douglas E. ; Hendrickx, Wouter R. ; Cesano, Alessandra ; Butterfield, Lisa H. ; Kaufman, Howard L. ; Hudson, Thomas J. ; Bedognetti, Davide ; Marincola, Francesco ; Samayoa, Josue. / Immune oncology, immune responsiveness and the theory of everything. In: Journal for ImmunoTherapy of Cancer. 2018 ; Vol. 6, No. 1.
@article{7c8887ed8353483393ecdfbba28e64cf,
title = "Immune oncology, immune responsiveness and the theory of everything",
abstract = "Anti-cancer immunotherapy is encountering its own checkpoint. Responses are dramatic and long lasting but occur in a subset of tumors and are largely dependent upon the pre-existing immune contexture of individual cancers. Available data suggest that three landscapes best define the cancer microenvironment: immune-active, immune-deserted and immune-excluded. This trichotomy is observable across most solid tumors (although the frequency of each landscape varies depending on tumor tissue of origin) and is associated with cancer prognosis and response to checkpoint inhibitor therapy (CIT). Various gene signatures (e.g. Immunological Constant of Rejection - ICR and Tumor Inflammation Signature - TIS) that delineate these landscapes have been described by different groups. In an effort to explain the mechanisms of cancer immune responsiveness or resistance to CIT, several models have been proposed that are loosely associated with the three landscapes. Here, we propose a strategy to integrate compelling data from various paradigms into a {"}Theory of Everything{"}. Founded upon this unified theory, we also propose the creation of a task force led by the Society for Immunotherapy of Cancer (SITC) aimed at systematically addressing salient questions relevant to cancer immune responsiveness and immune evasion. This multidisciplinary effort will encompass aspects of genetics, tumor cell biology, and immunology that are pertinent to the understanding of this multifaceted problem.",
keywords = "Cancer immunotherapy, Checkpoint inhibitors, Immune resistance",
author = "Tolga Turan and Deepti Kannan and Maulik Patel and {Matthew Barnes}, J. and Tanlimco, {Sonia G.} and Rongze Lu and Kyle Halliwill and Sarah Kongpachith and Kline, {Douglas E.} and Hendrickx, {Wouter R.} and Alessandra Cesano and Butterfield, {Lisa H.} and Kaufman, {Howard L.} and Hudson, {Thomas J.} and Davide Bedognetti and Francesco Marincola and Josue Samayoa",
year = "2018",
month = "6",
day = "5",
doi = "10.1186/s40425-018-0355-5",
language = "English",
volume = "6",
journal = "Journal for ImmunoTherapy of Cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Immune oncology, immune responsiveness and the theory of everything

AU - Turan, Tolga

AU - Kannan, Deepti

AU - Patel, Maulik

AU - Matthew Barnes, J.

AU - Tanlimco, Sonia G.

AU - Lu, Rongze

AU - Halliwill, Kyle

AU - Kongpachith, Sarah

AU - Kline, Douglas E.

AU - Hendrickx, Wouter R.

AU - Cesano, Alessandra

AU - Butterfield, Lisa H.

AU - Kaufman, Howard L.

AU - Hudson, Thomas J.

AU - Bedognetti, Davide

AU - Marincola, Francesco

AU - Samayoa, Josue

PY - 2018/6/5

Y1 - 2018/6/5

N2 - Anti-cancer immunotherapy is encountering its own checkpoint. Responses are dramatic and long lasting but occur in a subset of tumors and are largely dependent upon the pre-existing immune contexture of individual cancers. Available data suggest that three landscapes best define the cancer microenvironment: immune-active, immune-deserted and immune-excluded. This trichotomy is observable across most solid tumors (although the frequency of each landscape varies depending on tumor tissue of origin) and is associated with cancer prognosis and response to checkpoint inhibitor therapy (CIT). Various gene signatures (e.g. Immunological Constant of Rejection - ICR and Tumor Inflammation Signature - TIS) that delineate these landscapes have been described by different groups. In an effort to explain the mechanisms of cancer immune responsiveness or resistance to CIT, several models have been proposed that are loosely associated with the three landscapes. Here, we propose a strategy to integrate compelling data from various paradigms into a "Theory of Everything". Founded upon this unified theory, we also propose the creation of a task force led by the Society for Immunotherapy of Cancer (SITC) aimed at systematically addressing salient questions relevant to cancer immune responsiveness and immune evasion. This multidisciplinary effort will encompass aspects of genetics, tumor cell biology, and immunology that are pertinent to the understanding of this multifaceted problem.

AB - Anti-cancer immunotherapy is encountering its own checkpoint. Responses are dramatic and long lasting but occur in a subset of tumors and are largely dependent upon the pre-existing immune contexture of individual cancers. Available data suggest that three landscapes best define the cancer microenvironment: immune-active, immune-deserted and immune-excluded. This trichotomy is observable across most solid tumors (although the frequency of each landscape varies depending on tumor tissue of origin) and is associated with cancer prognosis and response to checkpoint inhibitor therapy (CIT). Various gene signatures (e.g. Immunological Constant of Rejection - ICR and Tumor Inflammation Signature - TIS) that delineate these landscapes have been described by different groups. In an effort to explain the mechanisms of cancer immune responsiveness or resistance to CIT, several models have been proposed that are loosely associated with the three landscapes. Here, we propose a strategy to integrate compelling data from various paradigms into a "Theory of Everything". Founded upon this unified theory, we also propose the creation of a task force led by the Society for Immunotherapy of Cancer (SITC) aimed at systematically addressing salient questions relevant to cancer immune responsiveness and immune evasion. This multidisciplinary effort will encompass aspects of genetics, tumor cell biology, and immunology that are pertinent to the understanding of this multifaceted problem.

KW - Cancer immunotherapy

KW - Checkpoint inhibitors

KW - Immune resistance

UR - http://www.scopus.com/inward/record.url?scp=85048141515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048141515&partnerID=8YFLogxK

U2 - 10.1186/s40425-018-0355-5

DO - 10.1186/s40425-018-0355-5

M3 - Article

AN - SCOPUS:85048141515

VL - 6

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

SN - 2051-1426

IS - 1

M1 - 50

ER -